http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019262479-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56f140885185b99c3f84f3cbb2ed61e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a118c7c21c037a30961979b3f04076e1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0453 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate | 2018-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c08ec14ff1b5c92eaa1b419022069af9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_192995fd635287c7525dbb121b38b278 |
| publicationDate | 2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019262479-A1 |
| titleOfInvention | Imaging method for diffuse intrinsic pontine glioma using an imaging agent, and imaging agents for early stage diagnoses |
| abstract | The present invention provides an in vivo imaging method that facilitates the diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) at an early stage. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms. The present invention also provides methods for producing an in vivo imaging agent useful for early diagnosis of DIPG, where embodiments of the imaging agent include a lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety, and embodiments including [18F]FMISO as the lipophilic azomycin-based hypoxic cell sensitizer labelled with an in vivo imaging moiety. |
| priorityDate | 2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.